Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin

Marta Johnson, Dipal Patel, Christopher Matheny, May Ho, Liangfu Chen and Harma Ellens
Drug Metabolism and Disposition January 2017, 45 (1) 27-34; DOI: https://doi.org/10.1124/dmd.116.072397
Marta Johnson
Drug Metabolism and Pharmacokinetics (M.J., D.P., M.H., L.C., H.E.), and Translational Medicine (C.M.), GlaxoSmithKline, King of Prussia, Pennsylvania; and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pennington, New Jersey (D.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dipal Patel
Drug Metabolism and Pharmacokinetics (M.J., D.P., M.H., L.C., H.E.), and Translational Medicine (C.M.), GlaxoSmithKline, King of Prussia, Pennsylvania; and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pennington, New Jersey (D.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Matheny
Drug Metabolism and Pharmacokinetics (M.J., D.P., M.H., L.C., H.E.), and Translational Medicine (C.M.), GlaxoSmithKline, King of Prussia, Pennsylvania; and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pennington, New Jersey (D.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
May Ho
Drug Metabolism and Pharmacokinetics (M.J., D.P., M.H., L.C., H.E.), and Translational Medicine (C.M.), GlaxoSmithKline, King of Prussia, Pennsylvania; and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pennington, New Jersey (D.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liangfu Chen
Drug Metabolism and Pharmacokinetics (M.J., D.P., M.H., L.C., H.E.), and Translational Medicine (C.M.), GlaxoSmithKline, King of Prussia, Pennsylvania; and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pennington, New Jersey (D.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harma Ellens
Drug Metabolism and Pharmacokinetics (M.J., D.P., M.H., L.C., H.E.), and Translational Medicine (C.M.), GlaxoSmithKline, King of Prussia, Pennsylvania; and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pennington, New Jersey (D.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Rosuvastatin is a widely prescribed antihyperlipidemic which undergoes limited metabolism, but is an in vitro substrate of multiple transporters [organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, OATP1A2, OATP2B1, sodium-taurocholate cotransporting polypeptide, breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), MRP4, organic anion transporter 3]. It is therefore frequently used as a probe substrate in clinical drug-drug interaction (DDI) studies to investigate transporter inhibition. Although each of these transporters is believed to play a role in rosuvastatin disposition, multiple pharmacogenetic studies confirm that OATP1B1 and BCRP play an important role in vivo. Ronacaleret, a drug-development candidate for treatment of osteoporosis (now terminated), was shown to inhibit OATP1B1 in vitro (IC50 = 11 µM), whereas it did not inhibit BCRP. Since a DDI risk through inhibition of OATP1B1 could not be discharged, a clinical DDI study was performed with rosuvastatin before initiation of phase II trials. Unexpectedly, coadministration with ronacaleret decreased rosuvastatin exposure by approximately 50%, whereas time of maximal plasma concentration and terminal half-life remained unchanged, suggesting decreased absorption and/or enhanced first-pass elimination of rosuvastatin. Of the potential in vivo rosuvastatin transporter pathways, two might explain the observed results: intestinal OATP2B1 and hepatic MRP4. Further investigations revealed that ronacaleret inhibited OATP2B1 (in vitro IC50 = 12 µM), indicating a DDI risk through inhibition of absorption. Ronacaleret did not inhibit MRP4, discharging the possibility of enhanced first-pass elimination of rosuvastatin (reduced basolateral secretion from hepatocytes into blood). Therefore, a likely mechanism of the observed DDI is inhibition of intestinal OATP2B1, demonstrating the in vivo importance of this transporter in rosuvastatin absorption in humans.

Footnotes

    • Received July 25, 2016.
    • Accepted October 12, 2016.
  • dx.doi.org/10.1124/dmd.116.072397.

  • Embedded ImageThis article has supplemental material available at dmd.aspetjournals.org.

  • Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 45 (1)
Drug Metabolism and Disposition
Vol. 45, Issue 1
1 Jan 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Decreased Rosuvastatin Exposure through OATP2B1 Inhibition

Marta Johnson, Dipal Patel, Christopher Matheny, May Ho, Liangfu Chen and Harma Ellens
Drug Metabolism and Disposition January 1, 2017, 45 (1) 27-34; DOI: https://doi.org/10.1124/dmd.116.072397

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Decreased Rosuvastatin Exposure through OATP2B1 Inhibition

Marta Johnson, Dipal Patel, Christopher Matheny, May Ho, Liangfu Chen and Harma Ellens
Drug Metabolism and Disposition January 1, 2017, 45 (1) 27-34; DOI: https://doi.org/10.1124/dmd.116.072397
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Functional Characterization of 29 CYP4F2 Variants
  • Exposure-toxicity relation of apatinib
  • ABC phenomenon potentiates anti-HCC efficacy
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics